 Christopher Codispoti
Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 13 | 2021 | 182 | 3.310 |
Why?
| | Rhinitis | 7 | 2019 | 164 | 2.040 |
Why?
| | Sinusitis | 7 | 2019 | 188 | 1.800 |
Why?
| | Pandemics | 3 | 2020 | 203 | 1.570 |
Why?
| | Coronavirus Infections | 2 | 2020 | 97 | 1.360 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 102 | 1.350 |
Why?
| | Allergens | 4 | 2019 | 20 | 1.290 |
Why?
| | Cost-Benefit Analysis | 2 | 2021 | 153 | 1.030 |
Why?
| | Anti-Asthmatic Agents | 2 | 2020 | 35 | 0.940 |
Why?
| | Nasal Polyps | 3 | 2019 | 53 | 0.910 |
Why?
| | Rhinitis, Allergic | 3 | 2018 | 22 | 0.860 |
Why?
| | Drug Hypersensitivity | 2 | 2019 | 18 | 0.850 |
Why?
| | Influenza, Human | 1 | 2020 | 52 | 0.800 |
Why?
| | Dyspnea | 1 | 2020 | 35 | 0.790 |
Why?
| | Education, Medical, Continuing | 1 | 2020 | 47 | 0.770 |
Why?
| | Biological Therapy | 1 | 2019 | 6 | 0.760 |
Why?
| | Asthma, Aspirin-Induced | 1 | 2019 | 5 | 0.760 |
Why?
| | Hypersensitivity | 1 | 2020 | 54 | 0.760 |
Why?
| | Desensitization, Immunologic | 1 | 2019 | 6 | 0.760 |
Why?
| | Penicillium | 2 | 2015 | 3 | 0.710 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 136 | 0.700 |
Why?
| | Air Pollutants | 2 | 2014 | 11 | 0.650 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 50 | 0.650 |
Why?
| | Poverty | 1 | 2017 | 104 | 0.630 |
Why?
| | Electronic Health Records | 1 | 2017 | 82 | 0.630 |
Why?
| | Residence Characteristics | 1 | 2017 | 226 | 0.600 |
Why?
| | Eosinophilia | 2 | 2018 | 49 | 0.590 |
Why?
| | Patient Selection | 1 | 2017 | 264 | 0.590 |
Why?
| | Acer | 1 | 2015 | 1 | 0.570 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2015 | 7 | 0.570 |
Why?
| | Vehicle Emissions | 1 | 2014 | 2 | 0.560 |
Why?
| | Humans | 26 | 2021 | 31481 | 0.560 |
Why?
| | Air Pollution | 1 | 2014 | 15 | 0.550 |
Why?
| | Adrenal Cortex Hormones | 3 | 2019 | 100 | 0.480 |
Why?
| | Chronic Disease | 7 | 2019 | 544 | 0.470 |
Why?
| | Male | 18 | 2020 | 17583 | 0.430 |
Why?
| | Hypersensitivity, Immediate | 1 | 2010 | 6 | 0.410 |
Why?
| | Adult | 13 | 2020 | 9779 | 0.400 |
Why?
| | Environmental Exposure | 1 | 2010 | 17 | 0.400 |
Why?
| | Skin Tests | 3 | 2015 | 16 | 0.380 |
Why?
| | Alendronate | 2 | 2019 | 8 | 0.380 |
Why?
| | Female | 16 | 2020 | 18253 | 0.360 |
Why?
| | Lung | 2 | 2020 | 171 | 0.360 |
Why?
| | Breast Feeding | 1 | 2010 | 177 | 0.330 |
Why?
| | Income | 2 | 2017 | 77 | 0.320 |
Why?
| | Child, Preschool | 3 | 2015 | 786 | 0.310 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2018 | 72 | 0.310 |
Why?
| | Parents | 2 | 2018 | 111 | 0.280 |
Why?
| | Severity of Illness Index | 3 | 2020 | 1240 | 0.280 |
Why?
| | Inhalation Exposure | 2 | 2014 | 6 | 0.240 |
Why?
| | Middle Aged | 11 | 2018 | 11209 | 0.240 |
Why?
| | Quality-Adjusted Life Years | 1 | 2021 | 25 | 0.220 |
Why?
| | United States | 2 | 2019 | 2539 | 0.210 |
Why?
| | Outpatients | 1 | 2021 | 56 | 0.210 |
Why?
| | Influenza Vaccines | 1 | 2020 | 14 | 0.210 |
Why?
| | Aspirin | 2 | 2019 | 90 | 0.210 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2020 | 12 | 0.210 |
Why?
| | Vaccination | 1 | 2020 | 43 | 0.210 |
Why?
| | Histamine Antagonists | 1 | 2020 | 5 | 0.200 |
Why?
| | Sulfides | 1 | 2020 | 13 | 0.200 |
Why?
| | Prospective Studies | 3 | 2015 | 1934 | 0.200 |
Why?
| | Quinolines | 1 | 2020 | 18 | 0.200 |
Why?
| | Acetates | 1 | 2020 | 26 | 0.200 |
Why?
| | Cyclopropanes | 1 | 2020 | 27 | 0.200 |
Why?
| | Albuterol | 1 | 2020 | 17 | 0.200 |
Why?
| | Risk | 1 | 2020 | 228 | 0.200 |
Why?
| | Education, Distance | 1 | 2020 | 18 | 0.200 |
Why?
| | Interleukin-5 | 1 | 2019 | 10 | 0.190 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2019 | 8 | 0.190 |
Why?
| | Phenotype | 2 | 2017 | 379 | 0.190 |
Why?
| | United States Food and Drug Administration | 1 | 2019 | 75 | 0.180 |
Why?
| | Child | 3 | 2018 | 1572 | 0.180 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 111 | 0.180 |
Why?
| | Nocturnal Myoclonus Syndrome | 1 | 2018 | 7 | 0.170 |
Why?
| | Health Services Accessibility | 1 | 2019 | 113 | 0.170 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 47 | 0.170 |
Why?
| | Health Information Exchange | 1 | 2017 | 4 | 0.170 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 456 | 0.170 |
Why?
| | Polysomnography | 1 | 2018 | 110 | 0.170 |
Why?
| | Nose | 1 | 2018 | 35 | 0.170 |
Why?
| | Chicago | 2 | 2018 | 955 | 0.170 |
Why?
| | Observer Variation | 1 | 2017 | 146 | 0.170 |
Why?
| | Aged | 5 | 2018 | 10295 | 0.160 |
Why?
| | Cooperative Behavior | 1 | 2017 | 86 | 0.160 |
Why?
| | Physicians | 1 | 2018 | 120 | 0.160 |
Why?
| | Cholecalciferol | 1 | 2016 | 3 | 0.150 |
Why?
| | Decision Making | 1 | 2018 | 232 | 0.150 |
Why?
| | Paranasal Sinus Diseases | 1 | 2016 | 15 | 0.150 |
Why?
| | Gastroesophageal Reflux | 1 | 2016 | 35 | 0.150 |
Why?
| | Adolescent | 3 | 2018 | 2667 | 0.150 |
Why?
| | Assertiveness | 1 | 2015 | 9 | 0.150 |
Why?
| | Infant | 2 | 2015 | 642 | 0.150 |
Why?
| | Retrospective Studies | 4 | 2018 | 3591 | 0.150 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2015 | 8 | 0.150 |
Why?
| | African Americans | 2 | 2020 | 818 | 0.140 |
Why?
| | Alternaria | 1 | 2014 | 3 | 0.140 |
Why?
| | Cohort Studies | 2 | 2018 | 2014 | 0.140 |
Why?
| | Nasal Mucosa | 1 | 2015 | 19 | 0.140 |
Why?
| | Behavior Therapy | 1 | 2015 | 86 | 0.140 |
Why?
| | Treatment Outcome | 3 | 2019 | 3910 | 0.140 |
Why?
| | Reproducibility of Results | 1 | 2017 | 886 | 0.140 |
Why?
| | Eosinophils | 1 | 2015 | 47 | 0.140 |
Why?
| | Pneumonia | 1 | 2015 | 74 | 0.140 |
Why?
| | Disease Progression | 1 | 2017 | 861 | 0.130 |
Why?
| | Anti-Bacterial Agents | 2 | 2015 | 412 | 0.130 |
Why?
| | Young Adult | 2 | 2018 | 2277 | 0.130 |
Why?
| | Hospitalization | 1 | 2016 | 359 | 0.120 |
Why?
| | Risk Factors | 3 | 2017 | 2664 | 0.110 |
Why?
| | Air Pollution, Indoor | 1 | 2010 | 2 | 0.100 |
Why?
| | Dust | 1 | 2010 | 4 | 0.100 |
Why?
| | Housing | 1 | 2010 | 20 | 0.100 |
Why?
| | Trees | 1 | 2010 | 21 | 0.100 |
Why?
| | Food | 1 | 2010 | 32 | 0.100 |
Why?
| | Penicillins | 1 | 2009 | 13 | 0.090 |
Why?
| | Administration, Inhalation | 2 | 2019 | 37 | 0.090 |
Why?
| | Aged, 80 and over | 1 | 2017 | 5234 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2009 | 180 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2019 | 559 | 0.080 |
Why?
| | Odds Ratio | 2 | 2018 | 327 | 0.070 |
Why?
| | Illinois | 2 | 2017 | 266 | 0.070 |
Why?
| | Quality Improvement | 2 | 2018 | 173 | 0.070 |
Why?
| | Prevalence | 2 | 2016 | 544 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2021 | 90 | 0.050 |
Why?
| | Inpatients | 1 | 2021 | 154 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2019 | 14 | 0.050 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2019 | 45 | 0.050 |
Why?
| | Sputum | 1 | 2018 | 23 | 0.050 |
Why?
| | Waist Circumference | 1 | 2018 | 34 | 0.040 |
Why?
| | Patient Participation | 1 | 2018 | 52 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 512 | 0.040 |
Why?
| | Microbiota | 1 | 2018 | 94 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 375 | 0.040 |
Why?
| | Vitamin D Deficiency | 1 | 2016 | 11 | 0.040 |
Why?
| | Comorbidity | 1 | 2018 | 562 | 0.040 |
Why?
| | Community Mental Health Services | 1 | 2015 | 20 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 362 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 82 | 0.040 |
Why?
| | Treatment Failure | 1 | 2016 | 187 | 0.040 |
Why?
| | Population Surveillance | 1 | 2016 | 127 | 0.040 |
Why?
| | Age Factors | 1 | 2018 | 943 | 0.040 |
Why?
| | Body Mass Index | 1 | 2018 | 458 | 0.040 |
Why?
| | Risk Assessment | 1 | 2018 | 806 | 0.030 |
Why?
| | Self Care | 1 | 2015 | 104 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 467 | 0.030 |
Why?
| | Intradermal Tests | 1 | 2009 | 1 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2009 | 40 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2009 | 281 | 0.020 |
Why?
| | Urban Population | 1 | 2009 | 161 | 0.020 |
Why?
| | Sex Factors | 1 | 2009 | 542 | 0.020 |
Why?
| | Animals | 1 | 2015 | 5312 | 0.020 |
Why?
|
|
Codispoti's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|